Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

NCT07385079 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

412

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Cancinoma (NPC)
Nasopharyngeal Cancer

Interventions

DRUG: Anlotinib Hydrochloride Capsules
DRUG: Gemcitabine (GEM)
DRUG: Cisplatin
RADIATION: Intensity-modulated radiotherapy
DRUG: Benmelstobart

Sponsor

Sun Yat-sen University